Posted by Michael Wonder on 13 Jul 2023
Semaglutide for the treatment of overweight and obese adolescents
13 July 2023 - NICE is unable to make a recommendation on the use of semaglutide (Wegovy) on the NHS for the treatment of overweight and obese adolescents aged 12-17 years because Novo Nordisk did not provide an evidence submission.
NICE will review this decision if Novo Nordisk decides to make a submission.
